Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA, CMS Coordination On Coverage Decisions May Improve Under McClellan

Executive Summary

FDA and the Centers for Medicare & Medicaid Services are likely to have a closer relationship under incoming Commissioner McClellan

You may also be interested in...



FDA’s McClellan To Head CMS: Will Greater FDA/CMS Cooperation Ensue?

FDA Commissioner McClellan's nomination to be administrator of the Centers for Medicare & Medicaid Services could usher in an era of increased cooperation between the two agencies

FDA’s McClellan To Head CMS: Will Greater FDA/CMS Cooperation Ensue?

FDA Commissioner McClellan's nomination to be administrator of the Centers for Medicare & Medicaid Services could usher in an era of increased cooperation between the two agencies

FDA/CMS Discussing Liaison Office To Improve Coverage Decisions

FDA is considering the creation of a liaison office to provide guidance to the Centers for Medicare & Medicaid Services on federal coverage decisions for new products

Related Content

UsernamePublicRestriction

Register

PS040611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel